<DOC>
	<DOC>NCT00878293</DOC>
	<brief_summary>The purpose of this trial is to determine whether the new centrally active analgesic and MS ContinusÂ® are effective in the treatment of painful diabetic polyneuropathy.</brief_summary>
	<brief_title>Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Subjects with pain at least NRS &gt;4 due to painful diabetic polyneuropaty. Contraindications to, or history of allergy or hypersensitivity to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USPNF or any compound planned to be used during the anesthesia, or their excipients. non Caucasian or Hispanic. Concomitant painful disease. Lifelong history of seizure disorder or epilepsy. Subjects with clinical relevant cardiac and vascular diseases. Subjects with impaired renal function Subjects with impaired hepatic function Female subjects who are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>analgesic</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>chronic neuropathic pain</keyword>
	<keyword>painful polyneuropathy caused by diabetes mellitus type I or II</keyword>
</DOC>